TRRAP

Summary

TRRAP (transformation/transcription domain associated protein, HGNC:12347) is a protein-coding gene on chromosome 7q22.1, encoding Transformation/transcription domain-associated protein (Q9Y4A5). Adapter protein, which is found in various multiprotein chromatin complexes with histone acetyltransferase activity (HAT), which gives a specific tag for epigenetic transcription activation. It is a common-essential gene (DepMap: required in 99.5% of cancer cell lines).

This gene encodes a large multidomain protein of the phosphoinositide 3-kinase-related kinases (PIKK) family. The encoded protein is a common component of many histone acetyltransferase (HAT) complexes and plays a role in transcription and DNA repair by recruiting HAT complexes to chromatin. Deregulation of this gene may play a role in several types of cancer including glioblastoma multiforme. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Source: NCBI Gene 8295 — RefSeq curated summary.

At a glance

• Gene–disease (curated): complex neurodevelopmental disorder with or without congenital anomalies (Definitive, ClinGen) — +3 more curated relationships
• GWAS associations: 9
• Clinical variants (ClinVar): 2,525 total — 6 pathogenic, 22 likely-pathogenic
• Phenotypes (HPO): 82
• Druggable target: yes
• Cancer driver (intOGen): activating (oncogene-like) across 9 cancer types
• Cancer dependency (DepMap): dependent in 99.5% of screened cell lines (common-essential)
• Dosage sensitivity (ClinGen): haploinsufficiency little evidence, triplosensitivity no evidence
• MANE Select transcript: NM_001375524

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12347
Approved symbol	TRRAP
Name	transformation/transcription domain associated protein
Location	7q22.1
Locus type	gene with protein product
Status	Approved
Aliases	TR-AP, PAF400, Tra1
Ensembl gene	ENSG00000196367
Ensembl biotype	protein_coding
OMIM	603015
Entrez	8295

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 7 protein_coding, 4 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000355540, ENST00000359863, ENST00000360902, ENST00000417523, ENST00000446306, ENST00000456197, ENST00000468960, ENST00000480695, ENST00000482799, ENST00000704587, ENST00000704588, ENST00000704589, ENST00000704590, ENST00000704591

RefSeq mRNA: 3 — MANE Select: NM_001375524 NM_001244580, NM_001375524, NM_003496

CCDS: CCDS5659, CCDS59066, CCDS94151

Canonical transcript exons

ENST00000456197 — 73 exons

Exon	Start	End
ENSE00000707847	98990455	98990619
ENSE00000707870	98994587	98994848
ENSE00000877592	98992137	98992227
ENSE00001040515	98983264	98983459
ENSE00001040520	98984944	98985044
ENSE00001040522	98984093	98984358
ENSE00001040547	98978211	98978323
ENSE00001040598	99011052	99011255
ENSE00001040599	99011341	99011535
ENSE00001040626	98981769	98981960
ENSE00001129829	99008377	99008561
ENSE00001129836	99005131	99005348
ENSE00001129842	99004190	99004415
ENSE00001129866	98988765	98988966
ENSE00001129897	98978769	98978904
ENSE00001130521	98881090	98881250
ENSE00001788909	98993538	98993737
ENSE00002435050	98897741	98897866
ENSE00002435169	98893798	98893881
ENSE00002435249	98962302	98962427
ENSE00002435742	98971799	98971945
ENSE00002436378	98912022	98912213
ENSE00002437795	98892424	98892528
ENSE00002438236	98900624	98900720
ENSE00002443265	98965696	98965895
ENSE00002445291	98910510	98910607
ENSE00002451058	98899422	98899499
ENSE00002451275	98967485	98967698
ENSE00002451463	98895764	98895820
ENSE00002451552	98957981	98958091
ENSE00002453494	98955098	98955304
ENSE00002457672	98956399	98956533
ENSE00002458269	98948566	98948685
ENSE00002459624	98927167	98927366
ENSE00002460354	98937650	98937820
ENSE00002461551	98964629	98964775
ENSE00002468522	98945747	98945800
ENSE00002470518	98903379	98903517
ENSE00002471402	98930633	98930830
ENSE00002473053	98906177	98906255
ENSE00002480022	98950064	98950262
ENSE00002480721	98945930	98945950
ENSE00002480975	98935579	98935675
ENSE00002481189	98910056	98910419
ENSE00002481320	98937156	98937277
ENSE00002481948	98949660	98949841
ENSE00002484714	98929989	98930206
ENSE00002497464	98921753	98921953
ENSE00002505616	98911077	98911271
ENSE00002507577	98949417	98949581
ENSE00002508171	98956146	98956304
ENSE00002508527	98970112	98970291
ENSE00002509616	98948221	98948340
ENSE00002515101	98908728	98908962
ENSE00002515185	98967041	98967162
ENSE00002516311	98953167	98953433
ENSE00002520529	98942949	98943017
ENSE00002521249	98915723	98915888
ENSE00002524424	98925112	98925263
ENSE00002527465	98950876	98951004
ENSE00002527984	98881975	98882024
ENSE00002530059	98959344	98959490
ENSE00002531277	98899679	98899767
ENSE00002531298	98890335	98890445
ENSE00002532570	98917423	98917679
ENSE00002533506	98976149	98976268
ENSE00002534519	98933241	98933402
ENSE00002535618	98961261	98961474
ENSE00002536497	98931405	98931665
ENSE00003515109	98976483	98976770
ENSE00003561271	98976939	98977076
ENSE00003900688	99012071	99013241
ENSE00003901887	98878532	98878637

Expression profiles

Bgee: expression breadth ubiquitous, 241 present calls, max score 89.39.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 26.7590 / max 362.0980, expressed in 1815 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
79836	12.3657	1798
79835	10.8025	1763
79838	3.2209	1429
79837	0.3699	185

Top tissues by expression

279 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ventricular zone	UBERON:0003053	89.39	gold quality
sural nerve	UBERON:0015488	88.94	gold quality
ganglionic eminence	UBERON:0004023	88.16	gold quality
endometrium epithelium	UBERON:0004811	87.98	gold quality
adenohypophysis	UBERON:0002196	87.21	gold quality
buccal mucosa cell	CL:0002336	86.86	silver quality
pituitary gland	UBERON:0000007	86.72	gold quality
upper leg skin	UBERON:0004262	86.63	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	86.33	gold quality
cortical plate	UBERON:0005343	86.08	gold quality
stromal cell of endometrium	CL:0002255	85.91	gold quality
right hemisphere of cerebellum	UBERON:0014890	85.31	gold quality
cerebellar hemisphere	UBERON:0002245	85.10	gold quality
granulocyte	CL:0000094	85.06	gold quality
cerebellar cortex	UBERON:0002129	84.98	gold quality
left ovary	UBERON:0002119	84.63	gold quality
skin of leg	UBERON:0001511	84.08	gold quality
right uterine tube	UBERON:0001302	84.03	gold quality
right ovary	UBERON:0002118	84.02	gold quality
skin of abdomen	UBERON:0001416	83.62	gold quality
Brodmann (1909) area 10	UBERON:0013541	83.46	silver quality
cerebellum	UBERON:0002037	83.18	gold quality
cartilage tissue	UBERON:0002418	83.18	gold quality
skin of hip	UBERON:0001554	82.86	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.82	gold quality
ovary	UBERON:0000992	82.82	gold quality
body of uterus	UBERON:0009853	82.78	gold quality
left lobe of thyroid gland	UBERON:0001120	82.54	gold quality
apex of heart	UBERON:0002098	82.26	gold quality
zone of skin	UBERON:0000014	82.25	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.07

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

2 targets.

Target	Regulation
CCND2	Activation
MITF	Repression

Upstream regulators (CollecTRI, top): KAT5, KAT7, MAX, MXD1, MYC, TBP, TP53

miRNA regulators (miRDB)

45 targeting TRRAP, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4476	100.00	68.18	2030
HSA-MIR-6876-5P	100.00	67.68	2126
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-6753-3P	99.93	66.57	637
HSA-MIR-7107-3P	99.93	66.73	627
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-4698	99.84	71.41	4303
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-4799-5P	99.82	70.60	2663
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-548BA	99.69	69.14	1514
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-6134	99.63	65.68	1537
HSA-MIR-4743-3P	99.62	68.12	2095
HSA-MIR-6832-3P	99.52	70.44	1726
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-32-3P	99.36	68.20	2517
HSA-MIR-4652-3P	99.33	70.02	2742
HSA-MIR-6815-3P	99.13	68.98	1530

Functional genomics

ClinGen dosage: haploinsufficiency 1 (little evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map DepMap (CRISPR cell-line fitness): dependent in 99.5% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 24)

• TRRAP binding and the recruitment of histone H3 and H4 acetyltransferase activities are required for the transactivation of a silent TERT gene in exponentially growing human fibroblasts by c-Myc or N-Myc protein. (PMID:12077335)
• Data suggest a model in which p53 directly recruits a TRRAP/acetyltransferase complex to the mdm2 gene to activate transcription. In addition, this study defines a novel mechanism utilized by the p53 tumor suppressor to regulate gene expression. (PMID:12138177)
• requirement in transcription activation via c-myc transformation domain (PMID:12660246)
• Results identify YL1 as a subunit of the TRRAP/TIP60 HAT complex, and also as a component of a novel mammalian multiprotein complex that includes the SNF2-related helicase SRCAP. (PMID:15647280)
• HAT cofactor Trrap and Tip60 HAT bind to the chromatin surrounding sites of DNA double-strand breaks (DSBs). Cells may use the same basic mechanism involving HAT complexes to regulate distinct cellular processes, such as transcription and DNA repair. (PMID:16341205)
• Several function of TRRAP during cellular process like: DNA repair, cell cycle, transcription etc… (PMID:17694078)
• NPAT recruits the TRRAP-Tip60 complex to histone gene promoters to coordinate the transcriptional activation of multiple histone genes during the G(1)/S-phase transition (PMID:17967892)
• Loss of Transduction; transformation-transcription domain-associated protein leads to a reduced level of beta-catenin ubiquitination, accumulation of beta-catenin protein and concomitant hyperactivation of the Wnt Proteins pathway. (PMID:19066453)
• knockdown of the adaptor protein TRRAP significantly increased differentiation of cultured brain tumor-initiating cells, sensitized the cells to apoptotic stimuli, and negatively affected cell cycle progression. (PMID:20085741)
• The over-expression of TRA1 in hepatocirrhosis and hepatocellular carcinoma is correlated with the formation and development of HCC. (PMID:20943076)
• TRRAP harbors a recurrent mutation that clustered in one position (p. Ser722Phe) in 6 out of 167 melanoma samples (approx. 4%). The nature, pattern and functional evaluation of the TRRAP recurrent mutation suggest that TRRAP functions as an oncogene. (PMID:21499247)
• TRRAP is targeted for destruction in a cell cycle-dependent fashion. (PMID:23318449)
• Findings establish Trrap as a critical part of the mechanism that restricts differentiation and promotes the maintenance of key features of ESCs. (PMID:23362228)
• study defined eight additional recurrently mutated genes in SMZL; these genes are CREBBP, CBFA2T3, AMOTL1, FAT4, FBXO11, PLA2G4D, TRRAP and USH2A. (PMID:24349473)
• MYC associates with STAGA through extended interactions of the TAD with both TRRAP and GCN5. (PMID:24705139)
• Data suggest that ubiquitin thioesterase 7 (HAUSP) may act as an oncogenic protein that can modulate c-MYC protein expression via transformation-transcription domain-associated protein (TRRAP). (PMID:25925205)
• TRRAP, an essential component of multiple histone acetyltransferase complexes, was identified as a central regulator of multiciliated cell formation. (PMID:29588376)
• TRRAP silencing attenuated p53 accumulation in lymphoma and colon cancer models, whereas TRRAP overexpression increased mutp53 levels, suggesting a role for TRRAP across cancer entities and p53 mutations. (PMID:29653964)
• TRRAP plays an important role in the regulation of the proliferation and stemness of ovarian cancer stem cells. (PMID:29936929)
• Missense Variants in the TRRAP gene Causes Autism and Syndromic Intellectual Disability. (PMID:30827496)
• Our results uncover a role for TRRAP/KAT5 in promoting hepatocellular carcinoma cell proliferation by activating mitotic genes. Targeting the TRRAP/KAT5 complex is a potential therapeutic strategy for hepatocellular carcinoma (PMID:31188495)
• Lipid droplet screen in human hepatocytes identifies TRRAP as a regulator of cellular triglyceride metabolism. (PMID:34156146)
• Beyond HAT Adaptor: TRRAP Liaisons with Sp1-Mediated Transcription. (PMID:34830324)
• Interaction of transcription factor FoxO3 with histone acetyltransferase complex subunit TRRAP modulates gene expression and apoptosis. (PMID:35151693)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	trrap	ENSDARG00000100623
mus_musculus	Trrap	ENSMUSG00000045482
rattus_norvegicus	Trrap	ENSRNOG00000025244
drosophila_melanogaster	Nipped-A	FBGN0053554

Paralogs (5): ATM (ENSG00000149311), SMG1 (ENSG00000157106), ATR (ENSG00000175054), MTOR (ENSG00000198793), PRKDC (ENSG00000253729)

Protein

Protein identifiers

Transformation/transcription domain-associated protein — Q9Y4A5 (reviewed: Q9Y4A5)

Alternative names: 350/400 kDa PCAF-associated factor, STAF40, Tra1 homolog

All UniProt accessions (10): A0A2R8YFJ4, A0A994J4K1, A0A994J4S5, A0A994J575, A0A994J759, A0A994J7J3, C9K0N1, Q9Y4A5, F2Z2U4, H0Y4W2

UniProt curated annotations — full annotation on UniProt →

Function. Adapter protein, which is found in various multiprotein chromatin complexes with histone acetyltransferase activity (HAT), which gives a specific tag for epigenetic transcription activation. Component of the NuA4 histone acetyltransferase complex which is responsible for acetylation of nucleosomal histones H4 and H2A. Plays a central role in MYC transcription activation, and also participates in cell transformation by MYC. Required for p53/TP53-, E2F1- and E2F4-mediated transcription activation. Also involved in transcription activation mediated by the adenovirus E1A, a viral oncoprotein that deregulates transcription of key genes. Probably acts by linking transcription factors such as E1A, MYC or E2F1 to HAT complexes such as STAGA thereby allowing transcription activation. Probably not required in the steps following histone acetylation in processes of transcription activation. May be required for the mitotic checkpoint and normal cell cycle progression. Component of a SWR1-like complex that specifically mediates the removal of histone H2A.Z/H2AZ1 from the nucleosome. May play a role in the formation and maintenance of the auditory system.

Subunit / interactions. Interacts with MYC, E2F1 and E2F4 transcription factors. Interacts directly with p53/TP53. Interacts with GCN5L2. Component of various HAT complexes. Component of the PCAF complex, at least composed of TADA2L/ADA2, SUPT3H, TADA3L/ADA3, TAF5L/PAF65-beta, TAF6L/PAF65-alpha, TAF10/TAFII30, TAF12/TAFII20, TAF9/TAFII31 and TRRAP. Component of the TFTC-HAT complex, at least composed of TAF5L, TAF6L, TADA3L, SUPT3H/SPT3, TAF2/TAFII150, TAF4/TAFII135, TAF5/TAFII100, GCN5L2/GCN5, TAF10 and TRRAP. Component of the NuA4 histone acetyltransferase complex which contains the catalytic subunit KAT5/TIP60 and the subunits EP400, TRRAP/PAF400, BRD8/SMAP, EPC1, DMAP1/DNMAP1, RUVBL1/TIP49, RUVBL2, ING3, actin, ACTL6A/BAF53A, MORF4L1/MRG15, MORF4L2/MRGX, MRGBP, YEATS4/GAS41, VPS72/YL1 and MEAF6. Component of the STAGA complex, at least composed of SUPT3H, GCN5L2, SUPT7L, TAF5L, TAF6L, TADA3L, TAD1L, TAF10, TAF12, TRRAP and TAF9. The STAGA core complex is associated with a subcomplex required for histone deubiquitination composed of ATXN7L3, ENY2 and USP22. Component of the BAF53 complex, at least composed of BAF53A, RUVBL1, SMARCA4/BRG1, and TRRAP, which preferentially acetylates histone H4 (and H2A) within nucleosomes. Interacts with NPAT. Interaction with TELO2 and TTI1. Component of a SWR1-like complex.

Subcellular location. Nucleus.

Disease relevance. TRRAP mutation Phe-722 has been frequently found in cutaneous malignant melanoma, suggesting that TRRAP may play a role in the pathogenesis of melanoma. Developmental delay with or without dysmorphic facies and autism (DEDDFA) [MIM:618454] An autosomal dominant neurodevelopmental disorder apparent from infancy or early childhood. Some patients present with intellectual disability and renal, cardiac, genitourinary systems, as well as structural brain abnormalities. In some cases, the phenotype is less severe, has no systemic involvement and is characterized by autism spectrum disorder and/or intellectual disability, sometimes associated with epilepsy. Affected individuals manifest variable dysmorphic features. The disease is caused by variants affecting the gene represented in this entry. Deafness, autosomal dominant, 75 (DFNA75) [MIM:618778] A form of non-syndromic deafness characterized by late-onset hearing loss that involves mid and high frequencies, and progresses to encompass all frequencies. The disease may be caused by variants affecting the gene represented in this entry.

Domain organisation. The PI3K/PI4K domain is required for the recruitment of HAT complexes, and the MYC-dependent transactivation. Although it is strongly related to the PI3/PI4-kinase family, it lacks the typical motifs that constitute the catalytic site of PI3/PI4-kinase proteins, and lacks such activity.

Similarity. Belongs to the PI3/PI4-kinase family. TRA1 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9Y4A5-1	1	yes
Q9Y4A5-2	2

RefSeq proteins (3): NP_001231509, NP_001362453, NP_003487 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000403	PI3/4_kinase_cat_dom	Domain
IPR003151	PIK-rel_kinase_FAT	Domain
IPR003152	FATC_dom	Domain
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR011989	ARM-like	Homologous_superfamily
IPR014009	PIK_FAT	Domain
IPR016024	ARM-type_fold	Homologous_superfamily
IPR046805	Tra1_ring	Repeat
IPR046807	Tra1_central	Repeat
IPR050517	DDR_Repair_Kinase	Family

Pfam: PF00454, PF02259, PF20175, PF20206

UniProt features (384 total): helix 239, strand 52, sequence variant 35, turn 32, region of interest 7, modified residue 5, compositionally biased region 4, domain 3, splice variant 2, initiator methionine 1, chain 1, short sequence motif 1, cross-link 1, sequence conflict 1

Structure

Experimental structures (PDB)

9 structures.

PDB	Method	Resolution (Å)
9CAF	ELECTRON MICROSCOPY	2.35
9RDK	ELECTRON MICROSCOPY	2.41
7KTR	ELECTRON MICROSCOPY	2.93
9CAD	ELECTRON MICROSCOPY	3.05
8XVV	ELECTRON MICROSCOPY	3.2
9C47	ELECTRON MICROSCOPY	3.4
8QRI	ELECTRON MICROSCOPY	3.5
8H7G	ELECTRON MICROSCOPY	3.7
8XVG	ELECTRON MICROSCOPY	9.4

Predicted structure (AlphaFold)

No AlphaFold model available for Q9Y4A5 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (6): 2, 1628, 2051, 2077, 3078, 2543

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-201722	Formation of the beta-catenin:TCF transactivating complex
R-HSA-3214847	HATs acetylate histones
R-HSA-5689880	Ub-specific processing proteases

MSigDB gene sets: 369 (showing top): GOBP_REGULATION_OF_DOUBLE_STRAND_BREAK_REPAIR, MORF_DNMT1, GOBP_REGULATION_OF_DNA_RECOMBINATION, NAGY_STAGA_COMPONENTS_HUMAN, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN, MITSIADES_RESPONSE_TO_APLIDIN_DN, GOBP_REGULATION_OF_DOUBLE_STRAND_BREAK_REPAIR_VIA_HOMOLOGOUS_RECOMBINATION, BILD_SRC_ONCOGENIC_SIGNATURE, GOBP_REGULATION_OF_DNA_REPAIR, ONKEN_UVEAL_MELANOMA_UP, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_REGULATION_OF_RESPONSE_TO_STRESS, DACOSTA_UV_RESPONSE_VIA_ERCC3_COMMON_DN, MORF_RFC4, GOBP_RNA_SPLICING

GO Biological Process (12): regulation of DNA repair (GO:0006282), regulation of DNA-templated transcription (GO:0006355), regulation of transcription by RNA polymerase II (GO:0006357), regulation of apoptotic process (GO:0042981), regulation of RNA splicing (GO:0043484), positive regulation of DNA-templated transcription (GO:0045893), regulation of cell cycle (GO:0051726), DNA repair-dependent chromatin remodeling (GO:0140861), positive regulation of double-strand break repair via homologous recombination (GO:1905168), regulation of double-strand break repair (GO:2000779), chromatin organization (GO:0006325), regulation of cellular response to stress (GO:0080135)

GO Molecular Function (3): transcription coregulator activity (GO:0003712), protein binding (GO:0005515), transferase activity (GO:0016740)

GO Cellular Component (8): SAGA complex (GO:0000124), nucleosome (GO:0000786), Swr1 complex (GO:0000812), nucleus (GO:0005634), nucleoplasm (GO:0005654), Golgi apparatus (GO:0005794), transcription factor TFTC complex (GO:0033276), NuA4 histone acetyltransferase complex (GO:0035267)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
TCF dependent signaling in response to WNT	1
Chromatin modifying enzymes	1
Deubiquitination	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
DNA-templated transcription	2
regulation of gene expression	2
regulation of DNA-templated transcription	2
regulation of cellular process	2
SAGA-type complex	2
intracellular membrane-bounded organelle	2
DNA repair	1
regulation of DNA metabolic process	1
regulation of cellular response to stress	1
regulation of RNA biosynthetic process	1
transcription by RNA polymerase II	1
apoptotic process	1
regulation of programmed cell death	1
RNA splicing	1
regulation of primary metabolic process	1
positive regulation of RNA biosynthetic process	1
cell cycle	1
chromatin remodeling	1
DNA damage response	1
double-strand break repair via homologous recombination	1
regulation of double-strand break repair via homologous recombination	1
positive regulation of DNA recombination	1
positive regulation of double-strand break repair	1
regulation of DNA repair	1
double-strand break repair	1
cellular component organization	1
cellular response to stress	1
regulation of response to stress	1
transcription regulator activity	1
binding	1
catalytic activity	1
DUBm complex	1
peptidase complex	1
chromatin	1
protein-DNA complex	1
histone deacetylase complex	1
nuclear chromosome	1
INO80-type complex	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

3565 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
TRRAP	KAT2A	Q92830	997
TRRAP	KAT5	Q92993	997
TRRAP	KAT2B	Q92831	996
TRRAP	RUVBL1	P82276	996
TRRAP	RUVBL2	Q9Y230	995
TRRAP	EP400	Q96L91	994
TRRAP	MYC	P01106	993
TRRAP	ACTL6A	O96019	975
TRRAP	DMAP1	Q9NPF5	961
TRRAP	TP53	P04637	948
TRRAP	MRGBP	Q9NV56	947
TRRAP	BRD8	Q9H0E9	934
TRRAP	VPS72	Q15906	929
TRRAP	TADA3	O75528	908
TRRAP	SUPT7L	O94864	873

IntAct

212 interactions, top by confidence:

A	B	Type	Score
MYC	MAX	psi-mi:“MI:0914”(association)	0.980
MYC	TRRAP	psi-mi:“MI:0915”(physical association)	0.890
TRRAP	MYC	psi-mi:“MI:0915”(physical association)	0.890
RUVBL1	ZNHIT1	psi-mi:“MI:0914”(association)	0.860
SGF29	NDC80	psi-mi:“MI:0914”(association)	0.840
MRGBP	YEATS4	psi-mi:“MI:0914”(association)	0.840
MRGBP	KAT5	psi-mi:“MI:0914”(association)	0.790
MRGBP	KAT5	psi-mi:“MI:0915”(physical association)	0.790
YEATS4	ZNHIT1	psi-mi:“MI:0914”(association)	0.790
H2AZ1	ZNHIT1	psi-mi:“MI:0914”(association)	0.770
TAF12	TAF4	psi-mi:“MI:0914”(association)	0.760
MRGBP	ACTL6A	psi-mi:“MI:0914”(association)	0.760
TRRAP	ATXN7	psi-mi:“MI:0914”(association)	0.740
TADA3	TADA2A	psi-mi:“MI:0914”(association)	0.740
ATXN7	TRRAP	psi-mi:“MI:0915”(physical association)	0.740
MBTD1	YEATS4	psi-mi:“MI:0914”(association)	0.730
MBTD1	MORF4L2	psi-mi:“MI:0914”(association)	0.730
MORF4L1	SIN3B	psi-mi:“MI:0914”(association)	0.730
ACTL6A	ZNHIT1	psi-mi:“MI:0914”(association)	0.720
ATXN7	TAF10	psi-mi:“MI:0914”(association)	0.690

BioGRID (1070): TRRAP (Affinity Capture-MS), TRRAP (Affinity Capture-MS), TRRAP (Affinity Capture-MS), TRRAP (Affinity Capture-MS), TRRAP (Affinity Capture-MS), TRRAP (Affinity Capture-MS), TRRAP (Affinity Capture-MS), TRRAP (Affinity Capture-MS), TRRAP (Affinity Capture-MS), TRRAP (Affinity Capture-MS), TRRAP (Affinity Capture-MS), TRRAP (Affinity Capture-MS), TRRAP (Affinity Capture-MS), TRRAP (Affinity Capture-MS), TRRAP (Affinity Capture-MS)

ESM2 similar proteins: A0A0R4ITC5, A1L1F4, A4L9P7, E9Q8I9, F1MKX4, F1QFR9, F1R2X6, F8VPU6, O94915, P21359, P42345, P42346, P51593, P97526, Q04690, Q14997, Q29RF7, Q2HJG5, Q498H0, Q4KLU7, Q4QXM3, Q4VA53, Q5F3U9, Q5F3V3, Q5R6J0, Q5SSW2, Q5TBA9, Q5U241, Q5VYK3, Q6A026, Q6DDM4, Q6GP04, Q6NRP2, Q6P4S8, Q6PDI5, Q6TRW4, Q7PX35, Q7TMY8, Q7Z3U7, Q7Z6Z7

Diamond homologs: A0A0R4ITC5, Q80YV3, Q8I8U7, Q9Y4A5

SIGNOR signaling

3 interactions.

A	Effect	B	Mechanism
CTNNB1	up-regulates	TRRAP	binding
TRRAP	“form complex”	“NuA4 complex”	binding
TRRAP	“form complex”	“SAGA complex”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 188 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
HATs acetylate histones	31	18.9×	1e-28
Chromatin organization	26	16.3×	3e-22
Chromatin modifying enzymes	27	15.0×	3e-22
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	5	11.6×	5e-03
Deubiquitination	9	8.6×	1e-04
Formation of the beta-catenin:TCF transactivating complex	8	7.4×	1e-03
B-WICH complex positively regulates rRNA expression	7	6.5×	6e-03
Regulation of TP53 Activity through Phosphorylation	7	6.3×	6e-03

GO biological processes:

GO term	Partners	Fold	FDR
regulation of double-strand break repair	15	49.0×	3e-20
regulation of DNA repair	21	32.6×	5e-24
positive regulation of double-strand break repair via homologous recombination	15	32.3×	7e-17
regulation of RNA splicing	17	20.9×	7e-16
regulation of DNA replication	8	16.5×	2e-06
regulation of embryonic development	8	14.8×	5e-06
cellular response to estradiol stimulus	5	11.6×	3e-03
positive regulation of transcription initiation by RNA polymerase II	7	10.7×	3e-04

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: activating (oncogene-like) across 9 cancer types — ACYC, ANGS, BLCA, CCRCC, CHOL, HNSC, LMS, LUAD, MEL.

Clinical variants and AI predictions

ClinVar

2525 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	6
Likely pathogenic	22
Uncertain significance	1100
Likely benign	1002
Benign	196

Top pathogenic / likely-pathogenic (28)

Variant ID	HGVS	Classification
3773953	NM_001375524.1(TRRAP):c.5852A>G (p.His1951Arg)	Pathogenic
634848	NM_001375524.1(TRRAP):c.2413C>T (p.Leu805Phe)	Pathogenic
634850	NM_001375524.1(TRRAP):c.5617T>A (p.Trp1873Arg)	Pathogenic
634851	NM_001375524.1(TRRAP):c.5619G>T (p.Trp1873Cys)	Pathogenic
870465	NM_001375524.1(TRRAP):c.3128C>T (p.Ala1043Val)	Pathogenic
992413	NM_001375524.1(TRRAP):c.3475G>A (p.Gly1159Arg)	Pathogenic
1067765	NM_001375524.1(TRRAP):c.3088G>A (p.Val1030Ile)	Likely pathogenic
1328554	NM_001375524.1(TRRAP):c.3093T>G (p.Ile1031Met)	Likely pathogenic
1328736	NM_001375524.1(TRRAP):c.9911C>T (p.Pro3304Leu)	Likely pathogenic
1685465	NM_001375524.1(TRRAP):c.3199C>T (p.Gln1067Ter)	Likely pathogenic
1687176	NM_001375524.1(TRRAP):c.1813-52T>A	Likely pathogenic
1802557	NM_001375524.1(TRRAP):c.3874C>A (p.Pro1292Thr)	Likely pathogenic
1805775	NM_001375524.1(TRRAP):c.5726T>G (p.Leu1909Arg)	Likely pathogenic
1992404	NM_001375524.1(TRRAP):c.3479G>T (p.Gly1160Val)	Likely pathogenic
2499613	NM_001375524.1(TRRAP):c.5816C>T (p.Pro1939Leu)	Likely pathogenic
2504138	NM_001375524.1(TRRAP):c.5722G>A (p.Val1908Ile)	Likely pathogenic
2574299	NM_001375524.1(TRRAP):c.3081_3087delinsTAAGGC (p.Met1027fs)	Likely pathogenic
3024225	NM_001375524.1(TRRAP):c.2622+1G>A	Likely pathogenic
3345952	NM_001375524.1(TRRAP):c.2766_2774del (p.Ser923_Thr925del)	Likely pathogenic
3369800	NM_001375524.1(TRRAP):c.7219A>G (p.Met2407Val)	Likely pathogenic
3778781	NM_001375524.1(TRRAP):c.6356_6358del (p.Thr2119del)	Likely pathogenic
3899981	NM_001375524.1(TRRAP):c.310G>T (p.Glu104Ter)	Likely pathogenic
3899982	NM_001375524.1(TRRAP):c.8734G>T (p.Glu2912Ter)	Likely pathogenic
3900014	NM_001375524.1(TRRAP):c.516C>G (p.Tyr172Ter)	Likely pathogenic
4686161	NM_001375524.1(TRRAP):c.10753G>T (p.Val3585Leu)	Likely pathogenic
689793	NM_001375524.1(TRRAP):c.3316G>A (p.Glu1106Lys)	Likely pathogenic
977633	NM_001375524.1(TRRAP):c.3103C>G (p.Arg1035Gly)	Likely pathogenic
984626	NM_001375524.1(TRRAP):c.5596C>T (p.Arg1866Cys)	Likely pathogenic

SpliceAI

13284 predictions. Top by Δscore:

Variant	Effect	Δscore
7:98881086:ATAG:A	acceptor_gain	1.0000
7:98881087:T:G	acceptor_gain	1.0000
7:98881087:TA:T	acceptor_loss	1.0000
7:98881088:A:AG	acceptor_gain	1.0000
7:98881088:AG:A	acceptor_gain	1.0000
7:98881088:AGG:A	acceptor_loss	1.0000
7:98881088:AGGCT:A	acceptor_gain	1.0000
7:98881089:G:GG	acceptor_gain	1.0000
7:98881089:GG:G	acceptor_gain	1.0000
7:98881089:GGC:G	acceptor_gain	1.0000
7:98881089:GGCT:G	acceptor_gain	1.0000
7:98881089:GGCTG:G	acceptor_gain	1.0000
7:98881246:TACAC:T	donor_gain	1.0000
7:98881248:CAC:C	donor_gain	1.0000
7:98881251:G:GG	donor_gain	1.0000
7:98890324:T:TA	acceptor_gain	1.0000
7:98890327:A:AG	acceptor_gain	1.0000
7:98890328:C:G	acceptor_gain	1.0000
7:98890329:A:AG	acceptor_gain	1.0000
7:98890330:A:G	acceptor_gain	1.0000
7:98890331:TTA:T	acceptor_loss	1.0000
7:98890332:TAGAA:T	acceptor_loss	1.0000
7:98890333:A:AG	acceptor_gain	1.0000
7:98890333:A:AT	acceptor_loss	1.0000
7:98890333:AGAAT:A	acceptor_gain	1.0000
7:98890334:G:GG	acceptor_gain	1.0000
7:98890334:GA:G	acceptor_gain	1.0000
7:98890334:GAA:G	acceptor_gain	1.0000
7:98890334:GAAT:G	acceptor_gain	1.0000
7:98890334:GAATG:G	acceptor_gain	1.0000

AlphaMissense

25591 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:98890369:T:C	L62P	1.000
7:98892431:G:C	R90P	1.000
7:98892437:T:C	L92P	1.000
7:98892443:T:C	L94P	1.000
7:98892459:A:C	R99S	1.000
7:98892459:A:T	R99S	1.000
7:98893815:T:A	N128K	1.000
7:98893815:T:G	N128K	1.000
7:98893829:T:C	L133P	1.000
7:98893832:G:C	R134T	1.000
7:98893832:G:T	R134I	1.000
7:98893847:T:C	L139P	1.000
7:98893854:A:C	K141N	1.000
7:98893854:A:T	K141N	1.000
7:98899440:G:A	G218R	1.000
7:98899440:G:C	G218R	1.000
7:98899441:G:A	G218E	1.000
7:98899450:C:T	S221F	1.000
7:98899464:G:C	A226P	1.000
7:98899467:G:A	E227K	1.000
7:98899473:C:A	P229T	1.000
7:98899474:C:A	P229H	1.000
7:98899474:C:G	P229R	1.000
7:98899483:T:A	V232D	1.000
7:98899486:T:A	V233D	1.000
7:98899707:T:A	V247D	1.000
7:98900670:G:C	A283P	1.000
7:98900671:C:A	A283D	1.000
7:98900679:A:G	K286E	1.000
7:98900680:A:T	K286I	1.000

dbSNP variants (sampled 300 via entrez): RS1000032060 (7:98946155 T>G), RS1000042333 (7:99010763 G>T), RS1000042943 (7:98912492 C>T), RS1000081423 (7:98894373 C>T), RS1000110303 (7:98989156 C>G,T), RS1000120134 (7:98989507 C>A), RS1000141756 (7:98977336 A>G), RS1000159054 (7:98983603 CG>C), RS1000225125 (7:98995274 T>C), RS1000249880 (7:98939731 C>T), RS1000253661 (7:98877997 G>A,T), RS1000257447 (7:98957907 G>A), RS1000265807 (7:98918345 C>A), RS1000286250 (7:98877630 C>G,T), RS1000336862 (7:98983005 G>A)

Disease associations

OMIM: gene MIM:603015 | disease phenotypes: MIM:618454, MIM:618778

GenCC curated gene-disease

Disease	Classification	Inheritance
developmental delay with or without dysmorphic facies and autism	Definitive	Autosomal dominant
autosomal dominant nonsyndromic hearing loss	Supportive	Autosomal dominant
hearing loss, autosomal dominant 75	Limited	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
complex neurodevelopmental disorder with or without congenital anomalies	Definitive	AD

Mondo (7): developmental delay with or without dysmorphic facies and autism (MONDO:0032760), hearing loss, autosomal dominant 75 (MONDO:0032911), prostate cancer (MONDO:0008315), complex neurodevelopmental disorder with or without congenital anomalies (MONDO:0100465), teratoma (MONDO:0002601), neurodevelopmental disorder (MONDO:0700092), autosomal dominant nonsyndromic hearing loss (MONDO:0019587)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

82 total (30 of 82 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000023	Inguinal hernia
HP:0000028	Cryptorchidism
HP:0000046	Small scrotum
HP:0000076	Vesicoureteral reflux
HP:0000089	Renal hypoplasia
HP:0000107	Renal cyst
HP:0000126	Hydronephrosis
HP:0000154	Wide mouth
HP:0000175	Cleft palate
HP:0000219	Thin upper lip vermilion
HP:0000252	Microcephaly
HP:0000286	Epicanthus
HP:0000316	Hypertelorism
HP:0000319	Smooth philtrum
HP:0000322	Short philtrum
HP:0000347	Micrognathia
HP:0000358	Posteriorly rotated ears
HP:0000365	Hearing impairment
HP:0000369	Low-set ears
HP:0000375	Abnormal cochlea morphology
HP:0000407	Sensorineural hearing impairment
HP:0000414	Bulbous nose
HP:0000426	Prominent nasal bridge
HP:0000431	Wide nasal bridge
HP:0000460	Narrow nose
HP:0000463	Anteverted nares
HP:0000490	Deeply set eye
HP:0000505	Visual impairment
HP:0000582	Upslanted palpebral fissure

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST004602_57	Mean corpuscular volume	2.000000e-09
GCST010083_213	Hemoglobin levels	1.000000e-13
GCST90002390_252	Mean corpuscular hemoglobin	4.000000e-13
GCST90002390_253	Mean corpuscular hemoglobin	4.000000e-13
GCST90002392_331	Mean corpuscular volume	7.000000e-15
GCST90002396_351	Mean reticulocyte volume	1.000000e-18
GCST90002396_352	Mean reticulocyte volume	3.000000e-18
GCST90002396_353	Mean reticulocyte volume	2.000000e-09
GCST90002397_303	Mean spheric corpuscular volume	5.000000e-17

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004509	hemoglobin measurement
EFO:0004527	mean corpuscular hemoglobin
EFO:0010701	mean reticulocyte volume

MeSH disease descriptors (3)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750
D013724	Teratoma	C04.557.465.910

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067383 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — TRRAP subfamily

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
5.76	Kd	1746	nM	CHEMBL5653589
5.76	ED50	1746	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2149663: Binding affinity to human TRRAP incubated for 45 mins by Kinobead based pull down assay	kd	1.7462	uM

CTD chemical–gene interactions

59 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects binding, affects folding, affects reaction, decreases reaction, decreases expression (+2 more)	4
Arsenic	affects methylation, decreases expression, increases abundance, increases expression	3
Benzo(a)pyrene	decreases expression, decreases methylation	3
Tretinoin	affects cotreatment, decreases expression	3
sodium arsenite	decreases expression, increases abundance, increases expression	2
bisphenol AF	decreases reaction, affects binding, affects folding, increases reaction	2
Cisplatin	decreases expression	2
Estradiol	affects binding, increases reaction	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Cadmium Chloride	decreases expression, increases expression	2
FR900359	increases phosphorylation	1
TAK-243	decreases sumoylation	1
ginger extract	decreases reaction, increases abundance, decreases expression	1
dicrotophos	increases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	decreases expression, increases oxidation, increases abundance, affects cotreatment	1
arsenite	affects binding, decreases reaction	1
sodium bichromate	decreases expression	1
nickel subsulfide	decreases expression	1
manganese chloride	decreases expression, increases abundance	1
ochratoxin A	decreases expression	1
coumarin	decreases phosphorylation	1
methacrylaldehyde	affects cotreatment, decreases expression, increases oxidation, increases abundance	1
beta-methylcholine	affects expression	1
cyanoginosin LR	increases expression	1
tamibarotene	decreases expression	1
CGP 52608	affects binding, increases reaction	1
bisphenol S	decreases methylation	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Bortezomib	decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5652705	Binding	Binding affinity to human TRRAP incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer